子宫颈癌患者新辅助化疗前后癌组织中mdr1、肺耐药蛋白mRNA及其蛋白的表达变化和意义 |
| |
引用本文: | 张岩,李宁.子宫颈癌患者新辅助化疗前后癌组织中mdr1、肺耐药蛋白mRNA及其蛋白的表达变化和意义[J].综合临床医学,2009(1):15-17. |
| |
作者姓名: | 张岩 李宁 |
| |
作者单位: | 遵义医学院附属医院肿瘤医院一病区,563003 |
| |
基金项目: | 贵州省科学技术基金项目(2004-3053) |
| |
摘 要: | 目的寻找预测子宫颈癌新辅助化疗效果的分子生物学指标。方法采用real time RT—PCR和免疫组织化学法检测40例子宫颈癌患者新辅助化疗前后癌组织中mdr1、肺耐药蛋白(LRP)mRNA及其编码蛋白P-gP、LRP表达水平。结果新辅助化疗前后子宫颈癌组织中mdr1的表达量分别为(45.800±0.636、62.381±0.743,t=-66.582,P〈0.01);新辅助化疗前后子宫颈癌组织中LRP mRNA的表达量分别为(50.048±0.770、66.912±0.752,t=-78.604,P〈0.01);新辅助化疗前后子宫颈癌组织中P-gP的阳性表达分别为40.0%(16/40)、70.0%(28/40),x^2=7.273,P=0.007;新辅助化疗前后子宫颈癌组织中LRP的阳性表达分别为62.5%(25/40)、92.5%(37/40),x^2=10.323,P=0.001,新辅助化疗后mdr1、LRPmRNA及其编码蛋白P-gP、LRP表达水平较化疗前明显升高,2组比较差异有统计学意义(P〈0.01)。P-gP、LRP表达与患者年龄、肿瘤大小、临床分期、病理分级无关(P〉0.05);P-gP蛋白的阳性与阴性患者其化疗有效率分别为6(37.5%)、17(70.8%),2组比较差异有统计学意义(x^2=4.365,P〈0.05)。LRP蛋白的阳性与阴性患者其化疗有效率分别为12(48.0%)、13(86.7%),2组比较差异有统计学意义(x^2=5.980,P〈0.05);P-gP与LRP成正相关(x^2=4.177,r=0.323,P〈0.05)。结论P-gP、LRP表达状态有可能作为预测化疗效果的参考指标。
|
关 键 词: | 子宫颈癌 mdr1 P-糖蛋白 肺耐药蛋白 新辅助化疗 |
Expression and significance of mdrl and lung resistance protein mRNA in cervical carcinoma before and after neoadjuvant chemotherapy. |
| |
Authors: | ZHANG Yan LI Ning |
| |
Institution: | .( Department l of Oncology, Affiliated Hospital, Oncology Hospital Zunyi Medical College ( Zunyi 563003, China)) |
| |
Abstract: | Objective To explore the biological parameter predicting the effect of neoadjuvant chemotherapy in cervieal carcinoma. Methods The expressions of the P-glueoprotein (P-gp) and lung resistance protein (LRP) as well mdrl and LRP mRNA were examined by real time RT-PCR and immunohistochemical assay in 40 specimens of cervical carcinoma before and after neoadjuvant ehemotherapy. Results The expression level of mdrl was (45. 800 ± 0.636 ) vs (62.381 ± 0.743 ), t = - 66. 582, P 〈 0.01 ], the expression level of LRP mRNA was 50.048 ± 0.770,66. 912 ± 0.752, t = - 78. 604, P 〈 0.01 ] before and after neoadjuvant chemotherapy The positive expression of P-gp was 40.0% (16 /40),70.0% (28/40), x^2 = 7. 273, P = 0. 007 ] and that of LRP was 62.5% (25/40) ,92.5% (37/40) ,x^2 = 10.323 ,P =0.001 ] ,which were significantly higher than that before neoadjuvant chemotherapy ( P 〈 0.01 ) ; the expressions of P-gp and LRP were irrelated to age, tumor size, TNM stage and pathology grade(P 〉 0.05 ) ; the effeetive rate of chemotherapy was 6 ( 37.5% ) in P-gp positive patients and 17 (70.8%)in P-gp negative patients ( x^2 = 4. 365, P 〈 0.05 ), while the effective rate of chemotherapy was 12 (48.0%) in LRP positive patients and 13 ( 86.7 % ) in LRP negative patients ( x^2 = 5. 980, P 〈 0.05 ). The expression of P-gp was positively correlated with the expressions of LRP ( x^2 = 4. 177, r = 0.323,P 〈 0.05 ). Conclusion The P-gp and LRP expression status can be used as a biological parameter to predict the effect of neoadjuvant chemotherapy. |
| |
Keywords: | Carcinoma cervicis Mdrl P- glucoprotein Lung resistance protein Neoadjuvant chemotherapy |
本文献已被 维普 等数据库收录! |
|